Bruno Tocque, ExonHit's President of the Management Board said, "The technical and management skills of our new collaborators, as well as their combined experience in the development of new diagnostics and in the service business will be of significant importance while we progress towards launching our first Alzheimer's disease diagnostic from blood."
On its own resources, ExonHit Therapeutics aims in 2008 at launching new whole-genome micro-arrays for rats and mice; at organizing its infrastructure in order to commercialize its first blood-based diagnostic for Alzheimer's disease; and at partnering its EHT0202 compound for the treatment of neurodegenerative disorders on the basis on the results of a first Phase II study for which the regulatory dossiers have been filed at the end of this year. At the same time, ExonHit expects that its longstanding collaboration with Allergan for the discovery, development and commercialization of drugs for the treatment of neurodegenerative diseases, pain and ophthalmology will result in further progress over the next two years.
The Management Board and the Supervisory Board have decided to set up
this new organization to best realize the value of the Company's
intellectual property portfolio. The founders expect to then transfer
leadership to a new Management Board that will be elected before March 31,
2008 to pursue a new entrepreneurial venture. " We have been working
closely with the founders in order to achieve this new organization" states
Laurent Condomine, Chairman of the Supervisory Board, he add
|SOURCE ExonHit Therapeutics SA|
Copyright©2008 PR Newswire.
All rights reserved